Concepts (112)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 10 | 2017 | 361 | 0.880 |
Why?
|
| Brain Neoplasms | 9 | 2018 | 647 | 0.650 |
Why?
|
| Glioblastoma | 5 | 2018 | 157 | 0.530 |
Why?
|
| Particle Accelerators | 2 | 2008 | 7 | 0.480 |
Why?
|
| Algorithms | 3 | 2008 | 511 | 0.360 |
Why?
|
| Lung Neoplasms | 5 | 2015 | 428 | 0.350 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2014 | 112 | 0.330 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2008 | 30 | 0.330 |
Why?
|
| Radiation Protection | 1 | 2008 | 6 | 0.290 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2008 | 51 | 0.280 |
Why?
|
| Radiopharmaceuticals | 1 | 2008 | 92 | 0.270 |
Why?
|
| Radiotherapy, High-Energy | 2 | 2008 | 4 | 0.260 |
Why?
|
| Photons | 2 | 2008 | 7 | 0.260 |
Why?
|
| Software | 1 | 2007 | 124 | 0.250 |
Why?
|
| Occupational Exposure | 1 | 2008 | 231 | 0.240 |
Why?
|
| Ultraviolet Rays | 1 | 2003 | 48 | 0.200 |
Why?
|
| Radiation Injuries | 2 | 2013 | 78 | 0.190 |
Why?
|
| Radiometry | 1 | 2002 | 40 | 0.190 |
Why?
|
| Radiotherapy Dosage | 6 | 2015 | 99 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2015 | 384 | 0.180 |
Why?
|
| Computer Simulation | 1 | 2002 | 223 | 0.180 |
Why?
|
| Skin | 1 | 2003 | 214 | 0.170 |
Why?
|
| Aged, 80 and over | 11 | 2017 | 4032 | 0.170 |
Why?
|
| Skin Neoplasms | 1 | 2003 | 217 | 0.170 |
Why?
|
| Thorax | 2 | 2014 | 30 | 0.170 |
Why?
|
| Genomics | 2 | 2018 | 88 | 0.160 |
Why?
|
| Aged | 15 | 2018 | 10538 | 0.160 |
Why?
|
| Middle Aged | 16 | 2018 | 12125 | 0.160 |
Why?
|
| Neoplasms | 1 | 2007 | 761 | 0.160 |
Why?
|
| Radiotherapy | 3 | 2015 | 82 | 0.140 |
Why?
|
| Humans | 20 | 2018 | 32798 | 0.140 |
Why?
|
| Retrospective Studies | 8 | 2017 | 3701 | 0.130 |
Why?
|
| Nervous System Neoplasms | 1 | 2017 | 8 | 0.130 |
Why?
|
| Salvage Therapy | 2 | 2015 | 134 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 80 | 0.130 |
Why?
|
| Male | 15 | 2018 | 19641 | 0.120 |
Why?
|
| Female | 15 | 2018 | 20261 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 16 | 0.120 |
Why?
|
| Adult | 10 | 2017 | 9560 | 0.110 |
Why?
|
| Disease-Free Survival | 4 | 2015 | 326 | 0.110 |
Why?
|
| Brain | 3 | 2013 | 946 | 0.110 |
Why?
|
| Mediastinal Neoplasms | 1 | 2014 | 13 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 1 | 2015 | 133 | 0.100 |
Why?
|
| Taste | 1 | 2013 | 17 | 0.100 |
Why?
|
| Smell | 1 | 2013 | 48 | 0.100 |
Why?
|
| Follow-Up Studies | 5 | 2017 | 2284 | 0.100 |
Why?
|
| Combined Modality Therapy | 5 | 2015 | 563 | 0.090 |
Why?
|
| Glioma | 1 | 2013 | 136 | 0.090 |
Why?
|
| Radiotherapy, Conformal | 1 | 2010 | 19 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2013 | 370 | 0.080 |
Why?
|
| Phantoms, Imaging | 2 | 2007 | 59 | 0.080 |
Why?
|
| Health Physics | 1 | 2008 | 4 | 0.070 |
Why?
|
| Ions | 1 | 2008 | 12 | 0.070 |
Why?
|
| Graphite | 1 | 2008 | 5 | 0.070 |
Why?
|
| Electrons | 1 | 2008 | 12 | 0.070 |
Why?
|
| Quality Control | 1 | 2008 | 43 | 0.070 |
Why?
|
| Survival Rate | 3 | 2018 | 894 | 0.070 |
Why?
|
| Equipment Design | 1 | 2008 | 179 | 0.070 |
Why?
|
| Young Adult | 4 | 2016 | 2730 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 412 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 167 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 947 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2008 | 180 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2015 | 1844 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 456 | 0.060 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2006 | 49 | 0.060 |
Why?
|
| Deoxycytidine | 1 | 2006 | 63 | 0.060 |
Why?
|
| Prognosis | 3 | 2018 | 1544 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2017 | 486 | 0.060 |
Why?
|
| Neoplasm Staging | 3 | 2014 | 470 | 0.060 |
Why?
|
| Disease Progression | 2 | 2018 | 594 | 0.060 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2015 | 82 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2003 | 576 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2017 | 3438 | 0.050 |
Why?
|
| Equipment Failure Analysis | 1 | 2003 | 42 | 0.050 |
Why?
|
| DNA Methylation | 2 | 2015 | 144 | 0.050 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2003 | 13 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 1307 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 1 | 2003 | 169 | 0.050 |
Why?
|
| Adolescent | 3 | 2016 | 3638 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2003 | 114 | 0.050 |
Why?
|
| Radiation Dosage | 1 | 2002 | 84 | 0.050 |
Why?
|
| Models, Biological | 1 | 2002 | 392 | 0.040 |
Why?
|
| Mice | 1 | 2003 | 2511 | 0.030 |
Why?
|
| Hearing Tests | 1 | 2017 | 13 | 0.030 |
Why?
|
| Cranial Irradiation | 1 | 2017 | 93 | 0.030 |
Why?
|
| DNA Modification Methylases | 1 | 2015 | 11 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2015 | 14 | 0.030 |
Why?
|
| Melanoma | 1 | 2017 | 165 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 369 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 70 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 220 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2014 | 29 | 0.030 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2014 | 35 | 0.030 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2014 | 40 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2014 | 156 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2013 | 288 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 363 | 0.020 |
Why?
|
| Animals | 1 | 2003 | 7569 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 1002 | 0.020 |
Why?
|
| Survivors | 1 | 2013 | 168 | 0.020 |
Why?
|
| Time Factors | 1 | 2016 | 2183 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 60 | 0.020 |
Why?
|
| Quinazolines | 1 | 2010 | 38 | 0.020 |
Why?
|
| Taxoids | 1 | 2010 | 55 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2010 | 134 | 0.020 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2007 | 10 | 0.020 |
Why?
|
| Esophagus | 1 | 2006 | 25 | 0.020 |
Why?
|
| Forced Expiratory Volume | 1 | 2006 | 89 | 0.020 |
Why?
|
| Lung | 1 | 2006 | 265 | 0.010 |
Why?
|
| United States | 1 | 2010 | 4108 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 767 | 0.010 |
Why?
|